EMBC

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Retrieved on: 
Wednesday, March 6, 2024
Knowledge, Division, Endocrinology, T2D, Inborn errors of metabolism, Metabolism, Education, Treatment, Insulin, Physician, Quality of life, ATTD, Faculty, DNP, University, Type 2 diabetes, EMBC, MDI, Fortezza, Case Western Reserve University, Patient, D.O, Poster, Needlestick injury, Risk, Lipohypertrophy, Obesity, Research, Fortezza da Basso, Time in Europe

Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.

Key Points: 
  • Additionally, six embecta-sponsored abstracts focusing on injection and insulin pump therapies have been selected for presentation as scientific posters at ATTD 2024.
  • Entitled “Unlocking the potential of insulin pumps for personalized T2D care,” the symposium aims to highlight the significance of insulin pump therapy among the extensive treatment options available for type 2 diabetes (T2D).
  • The six embecta-sponsored abstracts set for presentation as scientific posters, include robust data about insulin therapy via both pumps and multiple daily injections (MDI).
  • Another poster highlights data showing that in individuals with type 2 diabetes, insulin pump therapy eases constraints imposed by diabetes management and improves quality of life.

embecta Announces Quarterly Cash Dividend

Retrieved on: 
Friday, February 9, 2024
EMBC

PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock.

Key Points: 
  • PARSIPPANY, N.J., Feb. 09, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock.
  • The dividend is payable on March 15, 2024 to stockholders of record at the close of business on February 28, 2024.

embecta to Participate in the 11th Annual BTIG MedTech Conference

Retrieved on: 
Wednesday, February 7, 2024
EMBC

PARSIPPANY, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will host one-on-one investor meetings on Tuesday, February 13, 2024, at the Cliff Lodge, Snowbird, UT.

Key Points: 

PARSIPPANY, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will host one-on-one investor meetings on Tuesday, February 13, 2024, at the Cliff Lodge, Snowbird, UT.

embecta to Report Fiscal First Quarter 2024 Financial Results

Retrieved on: 
Wednesday, January 24, 2024
EMBC

PARSIPPANY, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, February 9, 2024.

Key Points: 
  • PARSIPPANY, N.J., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2024 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Friday, February 9, 2024.
  • A webcast replay of the call will be available beginning at 11:00 a.m.
  • ET on February 9, 2024, via the embecta investor relations website and archived on the website for one year.

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

Retrieved on: 
Tuesday, January 9, 2024
Diabetes, Insulin, Food, EMBC, Type 2 diabetes, D.O, Caregiver, FDA, Growth, Medical device

PARSIPPANY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system.

Key Points: 
  • PARSIPPANY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, today announced that it has submitted a 510(k) premarket filing to the U.S. Food and Drug Administration (FDA) for a proprietary disposable insulin delivery system.
  • "This patch pump is intended for people who require insulin to manage diabetes and is informed by the unique needs of people with type 2 diabetes and their healthcare providers," said Colleen Riley, Chief Technology Officer, embecta.
  • "We worked with them to address the needs of those who may require more daily insulin and are looking for a simplified and convenient option for automated insulin delivery that offers the ease of use and discretion of a patch pump, along with a larger 300U insulin reservoir."
  • embecta continues to advance its patch pump development program, with plans for a closed-loop version including an insulin-dosing algorithm in a future FDA submission.

embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Thursday, December 14, 2023
Conference, EMBC

PARSIPPANY, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 2:15 p.m. PT / 5:15 p.m. ET.

Key Points: 

PARSIPPANY, N.J., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 10, 2024 at 2:15 p.m. PT / 5:15 p.m. ET.

No embecta-made syringes impacted by FDA safety communication

Retrieved on: 
Friday, December 1, 2023
Workforce, FDA, Safety, SVP, Food, EMBC, Syringe, Communication, Sale, Pharmaceutical industry

PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:

Key Points: 
  • PARSIPPANY, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today issued the following statement regarding the U.S. Food and Drug Administration (FDA) Safety Communication on evaluation of certain plastic syringes:
    “embecta, the world’s largest manufacturer of plastic insulin syringes, manufactures all of our syringes distributed worldwide at our facility in Holdrege, Nebraska,” said Shaun Curtis, SVP, Global Manufacturing & Supply Chain.
  • “The safety notice issued by the FDA on November 30, 2023, only applies to plastic syringes made in China, and therefore has no impact on the ongoing production or sale of any embecta syringe products.”
    “In the coming year, embecta will mark 100 years since our predecessors developed the world’s first syringe dedicated to insulin delivery, and we are proud of our rich heritage of quality, reliability, and innovation that we have earned in the years since.
  • Our skilled workforce in Nebraska, with its unmatched expertise in high volume syringe manufacturing, is prepared to support any healthcare customers who may be affected by the FDA’s safety communication.”

embecta to Participate in Investor Conferences

Retrieved on: 
Wednesday, November 29, 2023
EMBC

PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events:

Key Points: 
  • PARSIPPANY, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global diabetes care company, today announced that management will participate in the following investor events:
    Management will host one-on-one investor meetings on Wednesday, December 6, 2023, at Sofitel Hotel, New York.
  • Management will host a fireside session on Monday, December 11, 2023, at 9:30 a.m. PT / 12:30 p.m.
  • ET at the Montage at Laguna Beach, California.

embecta Announces Quarterly Cash Dividend

Retrieved on: 
Tuesday, November 21, 2023
EMBC

PARSIPPANY, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock.

Key Points: 
  • PARSIPPANY, N.J., Nov. 21, 2023 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock.
  • The dividend is payable on December 15, 2023 to stockholders of record at the close of business on December 4, 2023.

IEEE EMBS Executive Committee Appoints Dr. Erika Ross Ellison as President-Elect, Along With Two New Vice Presidents

Retrieved on: 
Tuesday, December 19, 2023
Technology, Medical Devices, Science, Genetics, Biotechnology, Other Manufacturing, Health, Health Technology, Engineering, Other Science, Research, Nanotechnology, Manufacturing, Software, Hardware, Data Management, Artificial Intelligence, FH, Student, Biomedical sciences, Tetraplegia, Mayo Clinic, Electrical engineering, University, Machine learning, Bachelor of Science, Signal processing, UNSW, EMBC, Speech, Doctor of Philosophy, Conference, Texas A&M University, Telstra, Clinical, Telecommunications, Biology, School, Student activities, Woman, DRS, Applied science, University of Freiburg, Molecular biology, Quality, American Speech, Neurosurgery, Growth, Aalborg University, Medical device

Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.

Key Points: 
  • Beena Ahmed and Natalie Mrachacz-Kersting were elected vice president of Conferences and vice president of Member and Student Activities, respectively.
  • “My top objective will be to establish IEEE EMBS as the largest global forum for biomedical engineers, clinicians and scientists,” said Dr. Ross Ellison.
  • She is the technical representative on the IEEE EMBS administrative committee, and served as program co-chair of EMBC 2023.
  • She is an IEEE EMBS practitioner representative, and is active on the IEEE Brain steering committee.